Antibody Information
General Information of This Antibody
| Antibody ID | ANI0MCENE |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | huM25-S239C |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Leucine-rich repeat-containing protein 15 (LRRC15) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HuM25-S239C-PBD-E2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
60.13% (Day 13)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
EBC-1 squamous NSCLC cells (5 million) were implanted subcutaneously into SCID mice, and micewere randomized when the tumors reached 175 mm and dosed with ADC or isotype antibody at 0.6 mg/kg intraperitoneally on day 0.
|
||||
| In Vivo Model | EBC-1 CDX model | ||||
| In Vitro Model | Lung squamous cell carcinoma | EBC-1 cells | CVCL_2891 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
73.58% (Day 17)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
NCI-H1650 NSCLC cancer cells (5 million) were implanted subcutaneously into SCID/Beigemice. and mice were randomized when the tumors reached -200 mm and dosed on day 0 with isotype orADC at 0.1 mg/kg intraperitoneally.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
92.33% (Day 17)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
NCI-H1650 NSCLC cancer cells (5 million) were implanted subcutaneously into SCID/Beigemice. and mice were randomized when the tumors reached -200 mm and dosed on day 0 with isotype orADC at 0.3 mg/kg intraperitoneally.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
94.51% (Day 17)
|
High LRRC15 expression (LRRC15+++; IHC 3+) | ||
| Method Description |
NCI-H1650 NSCLC cancer cells (5 million) were implanted subcutaneously into SCID/Beigemice. and mice were randomized when the tumors reached -200 mm and dosed on day 0 with isotype orADC at 6 mg/kg intraperitoneally.
|
||||
| In Vivo Model | NCI-H1650 CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.00 pM
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
In vitro cell killing in LRRC15 transfected 3T12 cells by isotype-S239C-PBD-E2 or huM25-S239CPBD-E2. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Squamous non-small cell lung cancer | BALB/3T12-3 cells (huLRRC15 transfection) | CVCL_0637 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.00 nM-100.00 Nm
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
In vitro cell killing in A549 cells that have undergone epithelial tomesenchymal transition (EMT) in the presence of 10 ng/mL TGFB by isotype-S239C-PBD-E2huM25-S239C-PBD-E2, or huM25-S239C antibody.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.00 nM-100.00 Nm
|
Positive LRRC15 expression (LRRC15 +++/++) | ||
| Method Description |
In vitro cell killing in A549 lung cancer cells in the presence of 10 ng/mL TGFB by isotype-S239C-PBD-E2huM25-S239C-PBD-E2, or huM25-S239C antibody.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.